

12 December 2023

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES**Successful Completion of Retail Entitlement Offer**

Healius Limited (ASX:HLS) (**Healius**) is pleased to announce the successful completion of the retail component (**Retail Entitlement Offer**) of its fully underwritten¹ 1 for 3.65 pro-rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Healius (**New Shares**) as announced on Monday, 20 November 2023 (**Offer**).

The institutional component of the Offer (**Institutional Entitlement Offer**) was completed on Wednesday, 22 November 2023.

The Retail Entitlement Offer closed at 5:00pm (Sydney time) on Thursday, 7 December 2023 and raised a total of approximately A\$33.5 million at A\$1.20 per New Share. The total amount raised under the Institutional Entitlement Offer and the Retail Entitlement Offer is approximately A\$187 million.

A total of approximately 3,957 valid applications for retail entitlements were received from eligible retail shareholders, for approximately 16.9 million New Shares equating to approximately A\$20.3 million (including applications accepted under the retail oversubscription facility for approximately 2.3 million New Shares). This represents a total take-up rate by eligible retail shareholders of approximately 60%.

The approximately 11.1 million New Shares that were not taken up under the Retail Entitlement Offer will be allotted to sub-underwriters of the Retail Entitlement Offer, subject to the terms and conditions of the underwriting arrangements.

The approximately 28 million New Shares to be issued under the Retail Entitlement Offer are expected to be allotted on Thursday, 14 December 2023 and are expected to commence trading on ASX on a normal settlement basis from Friday, 15 December 2023. The New Shares will rank equally with existing Healius shares on issue.²

Holding statements for New Shares issued under the Retail Entitlement Offer are expected to be dispatched on Monday, 18 December 2023.

¹ Refer to "Shortfall" on slide 24 of the investor presentation released by Healius to ASX on Monday, 20 November 2023 for a description of the terms and conditions of the underwriting arrangements, including the handling of any excess shortfall shares.

² ASX has confirmed that, as a result of the off-market takeover bid (**Takeover Offer**) from Australian Clinical Labs Limited (**ACL**), the New Shares will be issued under a separate ticker, being 'HLSNB'. The New Shares will trade separately from the main class of Healius shares (unless the Takeover Offer lapses or ACL obtains relief from ASIC to extend the Takeover Offer to the New Shares). When the Takeover Offer ends or if ACL obtains relief from ASIC to extend the Takeover Offer to the New Shares, ASX will fold the New Shares into the main class of Healius shares. The Takeover Offer is currently scheduled to end on Thursday, 29 February 2024.

ENDS

The release of this announcement has been authorised by the Board.

For further information contact:

| | |
|--|---|
| Market and analysts: Janet Payne Group Executive, Corporate Affairs Mobile: +61 409 995 517 | Media: Andrew Butcher Bespoke Approach Mobile: +61 400 841 088 |
|--|---|

For over 30 years Healius has been one of Australia's leading healthcare companies, committed to supporting quality, affordable and accessible healthcare for all Australians. Today, Healius has two core diagnostics businesses, pathology and imaging. Through its unique footprint of centres and its 10,500 employees, Healius provides Australia-wide specialty diagnostic services to consumers and their referring practitioners.

Important Information

This announcement does not constitute or provide financial product advice and has been prepared without taking into account the particular investment objectives, financial situation or needs of any particular investor. Investors are encouraged to seek independent financial advice from their stockbroker, solicitor, accountant or other professional adviser before making any investment decision.

Not for release or distribution in the United States

This announcement has been prepared for publication in Australia and may not be released or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or in any jurisdiction in which such an offer would be unlawful. Any securities described in this announcement have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (**U.S. Securities Act**), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the entitlements may not be taken up or exercised by, and the New Shares may not be offered or sold, directly or indirectly, in the United States or to any person acting for the account or benefit of a person in the United States (to the extent that the person holds shares for the account or benefit of a person in the United States).